Fmr LLC held its position in Mirna Therapeutics, Inc. (NASDAQ:MIRN) during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 133,200 shares of the biotechnology company’s stock at the end of the first quarter. Fmr LLC’s holdings in Mirna Therapeutics were worth $292,000 as of its most recent filing with the SEC.

Mirna Therapeutics, Inc. (NASDAQ MIRN) opened at 1.74 on Thursday. The stock’s market capitalization is $36.29 million. Mirna Therapeutics, Inc. has a 12-month low of $1.12 and a 12-month high of $4.20. The stock’s 50 day moving average is $1.67 and its 200 day moving average is $1.91.

ILLEGAL ACTIVITY WARNING: “Fmr LLC Holds Stake in Mirna Therapeutics, Inc. (NASDAQ:MIRN)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at

Separately, Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 target price on shares of Mirna Therapeutics in a report on Thursday, April 13th. Six research analysts have rated the stock with a hold rating, Mirna Therapeutics presently has a consensus rating of “Hold” and an average target price of $3.63.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

Want to see what other hedge funds are holding MIRN? Visit to get the latest 13F filings and insider trades for Mirna Therapeutics, Inc. (NASDAQ:MIRN).

Institutional Ownership by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.